Harmony Biosciences Holdings, Inc.
$32.59-$0.39 (-1.2%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.9B
- P/E
- 12.0x
- EV / EBITDA
- 5.2x
- Revenue
- $868.5M
- Net margin
- 18.3%
- ROCE
- 20.4%
Price chart
Technical chartScreen technicals →-2.4% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -15.8%
- 3M
- -14.4%
- 6M
- +3.9%
- 1Y
- -2.4%
- 5Y
- -15.9%
52-week range
Day change -$0.39 (-1.2%) from $33 to $33 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in HRMY, bought on each weekday since 2021.
News & filings
What Harmony Biosciences Holdings filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthFree cash flow was 40.1% of revenue in fiscal 2025.
Concerns (1)
- Operating margin fell for three years, from 33.0% to 24.0%.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Read moreShow less
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
- Sector
- Healthcare
- Shares outstanding
- 57.5M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.9B
- P/E
- 12.0x
- P/B
- 2.2x
- EV / EBITDA
- 5.2x
- EV / Sales
- 1.5x
- P/S
- 2.2x
- 52-week high
- $42.86
- 52-week low
- $26.54
Profitability
- Operating margin
- 24.0%
- Net margin
- 18.3%
- EBITDA margin
- 29.4%
- ROE
- 18.2%
- ROCE
- 20.4%
- ROA
- 12.5%
- Asset turnover
- 0.68
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $868.5M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 21.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 25.6%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 9.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $347.9M
Solvency
- Current ratio
- 3.60
- Debt / Equity
- 0.19
- Debt / Assets
- 0.13
- CFO / Net profit
- 2.19
- Cash / Market cap
- 39.4%
Where the revenue went
Of every $100 of FY2025 revenue, $18 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $198.3M |
| Revenue | Gross profit | $670.1M |
| Gross profit | Research and development | $189.6M |
| Gross profit | Selling, general and administrative | $272.1M |
| Gross profit | Operating income | $208.5M |
| Operating income | Pretax income | $208.5M |
| Interest and other income | Pretax income | $6.6M |
| Pretax income | Tax and other | $56.4M |
| Pretax income | Net income | $158.7M |
Revenue and net profit
Revenue grew 21.5% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $437.9M | $181.5M |
| FY2023 | $582.0M | $128.9M |
| FY2024 | $714.7M | $145.5M |
| FY2025 | $868.5M | $158.7M |
Cash flows
FY2025: $348.2M from operations, $347.9M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $144.5M | $144.3M |
| FY2023 | $219.4M | $219.1M |
| FY2024 | $219.8M | $218.7M |
| FY2025 | $348.2M | $347.9M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $868.5M+21.5%1Y
- EBITDA
- $255.0M+9.3%1Y
- Net profit
- $158.7M+9.1%1Y
- Cash from operations
- $348.2M+58.4%1Y
- Free cash flow
- $347.9M+59.1%1Y
- Revenue CAGR, 3Y
- 25.6%
- Net profit CAGR, 3Y
- -4.4%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $868.5M | $255.0M | $158.7M | $347.9M | 18.2% | +21.5% | +9.1% |
Monthly returns
Month-by-month returns of HRMY across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $1.3B |
| Current assets | $907.0M |
| Non-current assets | $364.6M |
| Liabilities | $401.4M |
| Current liabilities | $252.1M |
| Non-current liabilities | $149.3M |
| Equity | $870.2M |
| Paid-in capital | $709.0M |
| Retained earnings | $160.9M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; HRMY highlighted.
P/E against peers
HRMY trades at 12.0x earnings against a peer median of -18.4x.
Not shown (no positive earnings and no EV / Sales): Trevi Therapeutics, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMYthis company | $1.9B | 12.0x | 2.2x | 18.2% | 5.2x |
| Trevi Therapeutics, Inc.TRVI | $2.0B | -46.3x | 10.8x | -23.3% | -45.9x |
| Iovance Biotherapeutics, Inc.IOVA | $2.0B | -5.0x | 2.8x | -56.0% | -5.2x |
| Ocular Therapeutix, Inc.OCUL | $1.9B | -7.2x | 2.9x | -40.6% | -5.1x |
| Astrana Health, Inc.ASTH | $1.9B | 83.5x | 2.4x | 2.9% | 18.7x |
| Stoke Therapeutics, Inc.STOK | $1.9B | -272.5x | 5.3x | -2.0% | -95.4x |
| Pulse Biosciences, Inc.PLSE | $1.9B | -25.6x | 23.1x | -90.2% | -23.6x |
| Zymeworks Inc.ZYME | $1.8B | -22.8x | 6.9x | -30.2% | -22.4x |
| Maravai LifeSciences Holdings, Inc.MRVI | $1.8B | -14.1x | 8.7x | -61.6% | -13.5x |
| Peer median | — | -18.4x | 6.1x | -35.4% | -17.9x |
Year-to-date ROI
HRMY since 1 January, against earlier years.
Historical volatility
HRMY's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 27.4% |
| FY2023 | 33.0% |
| FY2024 | 26.7% |
| FY2025 | 24.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $868.5M |
| Cost of revenueCost Of Revenue | $198.3M |
| Gross profitGross Profit | $670.1M |
| Operating expensesOperating Expense | $461.6M |
| Research and developmentResearch And Development | $189.6M |
| Selling, general and administrativeSelling General And Administration | $272.1M |
| Total expensesTotal Expenses | $660.0M |
| Operating incomeOperating Income | $208.5M |
| Interest and other | |
| Pretax incomePretax Income | $215.1M |
| TaxTax Provision | $56.4M |
| Net incomeNet Income | $158.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $1.3B |
| Current assetsCurrent Assets | $907.0M |
| Non-current assetsTotal Non Current Assets | $364.6M |
| LiabilitiesTotal Liabilities Net Minority Interest | $401.4M |
| Current liabilitiesCurrent Liabilities | $252.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $149.3M |
| EquityTotal Equity Gross Minority Interest | $870.2M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $348.2M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $348.2M |
| Net income, continuing operationsNet Income From Continuing Operations | $158.7M |
| Depreciation and amortisationDepreciation And Amortization | $25.3M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $25.3M |
| Depreciation | $1.5M |
| Amortization cash flowAmortization Cash Flow | $23.8M |
| Amortization of intangiblesAmortization Of Intangibles | $23.8M |
| Amortization of securitiesAmortization Of Securities | -$1.5M |
| Stock-based compensationStock Based Compensation | $44.9M |
| Deferred taxDeferred Tax | -$7.3M |
| Deferred income taxDeferred Income Tax | -$7.3M |
| Operating gains and lossesOperating Gains Losses | — |
| Change in working capitalChange In Working Capital | $91.8M |
| Other non-cash itemsOther Non Cash Items | $36.3M |
| Investing cash flowInvesting Cash Flow | -$39.6M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$39.6M |
| Capital expenditureCapital Expenditure | -$310.0k |
| Purchase of PP&EPurchase Of PPE | -$310.0k |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$310.0k |
| AcquisitionsPurchase Of Business | -$19.3M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$19.3M |
| Purchase of investmentsPurchase Of Investment | -$86.2M |
| Sale of investmentsSale Of Investment | $81.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$5.1M |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | -$15.0M |
| Financing cash flowFinancing Cash Flow | -$9.1M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$9.1M |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$16.3M |
| Net debt issuedNet Issuance Payments Of Debt | -$16.3M |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$16.3M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$16.3M |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $10.2M |
| Preferred stock issuancePreferred Stock Issuance | — |
| Net preferred stock issuanceNet Preferred Stock Issuance | — |
| Other financing chargesNet Other Financing Charges | -$3.0M |
| Change in cashChanges In Cash | $299.5M |
| Cash at the start of the yearBeginning Cash Position | $453.3M |
| Cash at the end of the yearEnd Cash Position | $752.8M |
| Free cash flowFree Cash Flow | $347.9M |
| Supplemental |
Learn while you research
Academy chapters picked for Harmony Biosciences Holdings, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Growth Investing22% revenue growth is in the top tier, learn how to value growth.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read